RE
VIRX

RBC Europe’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

RBC Europe’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-749
Closed -$6.01K – 1192
2021
Q3 		$6.01K Hold
749
– – ﹤0.01% 1019
2021
Q2 		$8.49K Hold
749
– – ﹤0.01% 984
2021
Q1 		$6.93K Sell
749
-1
-0.1% -$10 ﹤0.01% 966
2020
Q4 		$5.22K Hold
750
– – ﹤0.01% 967
2020
Q3 		$3.28K Buy
+750
New +$6.55K ﹤0.01% 940

Other funds holding VIRX

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RBC Europe's VIRX Position: Q4 2021 in Review

RBC Europe sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2021, closing a stake of 749 shares — an estimated $6.01K sold.

RBC Europe first reported a position in VIRX in Q3 2020 and held it in 5 quarters. The position peaked at $8.49K in Q2 2021. 69 funds tracked by Wall St. Rank hold VIRX as of Q4 2021.

  • RBC Europe reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 749 Viracta Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $6.01K.
  • RBC Europe first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
  • RBC Europe's Viracta Therapeutics, Inc. Common Stock position peaked at $8.49K in Q2 2021.
  • 69 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.